文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

贝伐珠单抗治疗早产儿视网膜病变的1期剂量研究:12个月眼部次要结局

Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

这项前瞻性队列研究采用设盲、多中心、1期剂量递减设计,于2016年4月至2017年10月对39名早产儿视网膜病变患儿分别给予0.25、0.125、0.063或0.031 mg贝伐珠单抗,对侧眼给予高一级剂量。61名婴儿中46名(75%)在矫正年龄12个月时完成随访,高近视、斜视、视网膜脱离、眼球震颤等次要结局与其他研究中较高剂量的报告率一致。

要点

  • 61名婴儿中46名(75%)完成12个月随访,中位出生体重650(IQR 590-760)g。
  • 87只眼中有12只(14%,95%CI 7%-27%)近视超过-5.00 D等效球镜。
  • 斜视13名(30%,95%CI 17%-45%),眼球震颤7名(15%,95%CI 6%-29%),弱视3名(7%,95%CI 1%-18%)。

核心结论

  • 在这项低剂量贝伐珠单抗研究中,1岁时高近视、斜视、视网膜脱离、眼球震颤及其他眼部异常的次要结局与其他较高剂量研究报告的发生率一致。

研究设计与样本

  • 前瞻性队列研究,采用设盲、多中心、1期剂量递减设计,于2016年4月至2017年10月开展。
  • 研究眼接受0.25、0.125、0.063或0.031 mg贝伐珠单抗,对侧眼接受比研究眼高1级的剂量。
  • 4周后的额外治疗由研究者决定;数据分析于2018年11月至2019年3月进行。
  • 61名婴儿中46名(75%)在矫正年龄12个月时完成随访检查,包括46只研究眼和43只对侧眼,中位出生体重650(IQR 590-760)g。

主要发现

  • 87只眼中有12只(14%,95%CI 7%-27%)近视超过-5.00 D等效球镜。
  • 87只眼中有2只(2%,95%CI 0%-8%)远视超过+5.00 D等效球镜,5名婴儿(11%,95%CI 4%-24%)有超过1.50 D等效球镜的屈光参差。
  • 角膜异常1只眼(1%,95%CI 0%-6%),晶状体异常3只眼(3%,95%CI 1%-10%),前节异常3只眼(3%,95%CI 1%-10%)。
  • 视神经萎缩11只眼(13%,95%CI 6%-26%),1只眼(1%,95%CI 0%-6%)发生全视网膜脱离。
  • 斜视13名婴儿(30%,95%CI 17%-45%),显性眼球震颤7名(15%,95%CI 6%-29%),弱视3名(7%,95%CI 1%-18%);98%的婴儿每只眼均有中心注视(45只眼中44只)。

关键数值与推荐

  • 近视超过-5.00 D等效球镜:12/87只眼(14%,95%CI 7%-27%)。
  • 远视超过+5.00 D等效球镜:2/87只眼(2%,95%CI 0%-8%)。
  • 屈光参差超过1.50 D等效球镜:5名婴儿(11%,95%CI 4%-24%)。
  • 视神经萎缩:11/87只眼(13%,95%CI 6%-26%);全视网膜脱离:1只眼(1%,95%CI 0%-6%)。
  • 斜视:13名婴儿(30%,95%CI 17%-45%);显性眼球震颤:7名(15%,95%CI 6%-29%);弱视:3名(7%,95%CI 1%-18%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lower bevacizumab dosages are being used for type 1 retinopathy of prematurity, but there are limited data on long-term ocular outcomes with lower doses. OBJECTIVE: To evaluate ocular outcomes at 12 months' corrected age for eyes that received a dose of 0.625 mg, 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg of bevacizumab for type 1 retinopathy of prematurity. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study used a masked, multicenter, phase 1 dose de-escalation study design and was conducted from April 2016 to October 2017. Study eyes were treated with a dose of 0.25, 0.125, 0.063, or 0.031 mg of bevacizumab; fellow eyes were treated with a dosage 1 level higher than the study eye. Additional treatment after 4 weeks was at investigator discretion. Data analysis occurred from November 2018 to March 2019. INTERVENTIONS: Intravitreous bevacizumab injections of 0.625 mg to 0.031 mg. MAIN OUTCOMES AND MEASURES: Visual fixation, amblyopia, alignment, nystagmus, cycloplegic refraction, and ocular examinations were assessed at 12 months' corrected age as preplanned secondary outcomes. The primary outcome 4 weeks after treatment and secondary outcomes after 6 months' corrected age have been previously reported. RESULTS: Forty-six of 61 infants (75%) had a 12-month follow-up examination (46 study eyes and 43 fellow eyes; median [interquartile range] birth weight, 650 [590-760] g). Of 87 eyes with a cycloplegic refraction, 12 (14% [95% CI, 7%-27%]) had myopia of more than -5.00 D spherical equivalent; 2 (2%; [95% CI, 0%-8%]) had hyperopia greater than 5.00 D spherical equivalent; and 5 infants (11% [95% CI, 4%-24%]) had anisometropia greater than 1.50 D spherical equivalent. Abnormalities of the cornea, lens, or anterior segment were reported in 1 eye (1% [95% CI, 0%-6%]), 3 eyes (3% [95% CI, 1%-10%]), and 3 eyes (3% [95% CI, 1%-10%]), respectively. Optic nerve atrophy was identified in 11 eyes (13% [95% CI, 6%-26%]), and 1 eye (1% [95% CI, 0%-6%]) had total retinal detachment. Strabismus was reported in 13 infants (30% [95% CI, 17%-45%]), manifest nystagmus in 7 infants (15% [95% CI, 6%-29%]), and amblyopia in 3 infants (7% [95% CI, 1%-18%]). Overall, 98% of infants had central fixation in each eye (44 of 45 eyes). CONCLUSIONS AND RELEVANCE: In this study of low-dose bevacizumab, the secondary outcomes of high myopia, strabismus, retinal detachment, nystagmus, and other ocular abnormalities at 1 year were consistent with rates reported in other studies with higher dosages. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02390531.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Crouch ER, Kraker RT, Wallace DK, et al. Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol. 2020. PMID: 31697304. doi:10.1001/jamaophthalmol.2019.4488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。